Development of a molecular platform for the detection and quantification of Newcastle vaccine virus

El estudio tuvo por objetivo desarrollar una plataforma molecular para la cuantificación del virus de la enfermedad de Newcastle (NDV) a partir de un sistema de cultivo en huevos embrionados SPF. Primero se evaluaron cuatro pares de cebadores que amplifican diferentes regiones del genoma viral de NDV que codifican para la proteína de nucleocápside (NP), proteína matriz (M), proteína fusión (F) y la ARN polimerasa ARN dependiente (L), con la finalidad de seleccionar el más conservado a partir del cual se desarrolló una plataforma molecular basada en la transcripción reversa - reacción en cadena de polimerasa convencional (RT-PCRc) en dos pasos para la detección del NDV. Posteriormente, esta fue llevada a transcripción reversa - reacción en cadena de polimerasa en tiempo real (RT-qPCR) para la cuantificación de NDV producido a partir de un sistema de huevos embrionados. Mediante estas técnicas se determinó que los cebadores para el gen M fueron adecuados según los criterios de optimización para el desarrollo de ambos métodos. Mediante ensayos de sensibilidad se demostró que la RT-qPCR (116 copias genómicas/μl) era 10 veces más sensible que el RT-PCRc. Los cebadores fueron específicos pues no hubo amplificados en los controles negativos ni en otros patógenos aviares (virus de la laringotraqueitis infecciosa, metapneumovirus aviar, virus de la bronquitis infecciosa, Avibacterium paragallinarum, Gallibacterium anatis y Ornithobacterium rhinotracheale). Debido su sensibilidad y especificidad, se propone esta plataforma para la cuantificación de NDV vacunal cuando es producido a partir de un sistema de huevos embrionados, como una alternativa frente a métodos convencionales de titulación como hemaglutinación, ensayo en placa, TCDI50 y DIEP50.The objective of the study was to develop a molecular platform for the quantification of Newcastle disease virus (NDV) from a culture system in embryonated SPF eggs. First, four pairs of primers were evaluated that amplify different regions of the NDV viral genome that code for: nucleocapsid protein (NP), protein matrix (M), fusion protein (F) and RNA-dependent RNA polymerase (L) to select the most conserved one from which a molecular platform based on reverse transcription was developed - conventional polymerase chain reaction (RT-PCRc) in two steps for the detection of NDV. Subsequently, it was taken to reverse transcription - real-time polymerase chain reaction (RT-qPCR) for the quantification of NDV produced from a system of embryonated eggs. Through these techniques, it was determined that the primers for the M gene were adequate according to the optimization criteria for the development of both methods. Sensitivity tests showed that the RT-qPCR (116 genomic copies/μl) was 10 times more sensitive than the RT-PCRc. The primers proved to be specific since there were no amplifications in the negative controls or in other avian pathogens (infectious laryngotracheitis virus, avian metapneumovirus, infectious bronchitis virus, Avibacterium paragallinarum, Gallibacterium anatis and Ornithobacterium rhinotracheale). Due to its sensitivity and specificity, this platform is proposed for the quantification of NDV vaccine when it is produced from an embryonated egg system, as an alternative to conventional titration methods such as hemagglutination, plaque assay, TCDI50 and DIEP50

A Recombinant Turkey Herpesvirus Expressing the F Protein of Newcastle Disease Virus Genotype XII Generated by NHEJ-CRISPR/Cas9 and Cre-LoxP Systems Confers Protection against Genotype XII Challenge in Chickens

In this study, we developed a new recombinant virus rHVT-F using a Turkey herpesvirus (HVT) vector, expressing the fusion (F) protein of the genotype XII Newcastle disease virus (NDV) circulating in Peru. We evaluated the viral shedding and efficacy against the NDV genotype XII challenge in specific pathogen-free (SPF) chickens. The F protein expression cassette was inserted in the unique long (UL) UL45–UL46 intergenic locus of the HVT genome by utilizing a clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 gene-editing technology via a non-homologous end joining (NHEJ) repair pathway. The rHVT-F virus, which expressed the F protein stably in vitro and in vivo, showed similar growth kinetics to the wild-type HVT (wtHVT) virus. The F protein expression of the rHVT-F virus was detected by an indirect immunofluorescence assay (IFA), Western blotting, and a flow cytometry assay. The presence of an NDV-specific IgY antibody was detected in serum samples by an enzyme-linked immunosorbent assay (ELISA) in SPF chickens vaccinated with the rHVT-F virus. In the challenge experiment, the rHVT-F vaccine fully protects a high, and significantly reduced, virus shedding in oral at 5 days post-challenge (dpc). In conclusion, this new rHVT-F vaccine candidate is capable of fully protecting SPF chickens against the genotype XII challenge